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The BvgAS system of Bordetella pertussis was traditionally considered to mediate a transition between two
phenotypic phases (Bvg and Bvg) in response to environmental signals. We characterized a third state, the
intermediate (Bvgi) phase, which can be induced by introducing a 1-bp substitution into bvgS (the bvgS-I1
mutation) or by growing B. pertussis under conditions intermediate between those leading to the Bvg and Bvg
phases. Like B. bronchiseptica, B. pertussis displays in its Bvgi phase a characteristic colony morphology and
hemolytic activity and expresses a Bvgi-phase-specific polypeptide called BipA, whose synthesis is regulated by
bvgAS at the transcriptional level. Based on our results, we hypothesize that the Bvgi phase of B. pertussis may
be involved in facilitating transmission between hosts. Thus, a B. pertussis mutant carrying the bvgS-I1
mutation (GMT1i) persisted at wild-type levels only in the upper murine respiratory tract. Interestingly, a bipA
deletion derivative of GMT1i displayed a reduced ability to colonize the nasal cavity of mice compared with
GMT1i. However, in experimental mixed infections GMT1i expressing the Bvgi phase could establish an initial
colonization in the nose and trachea of mice as efficiently as GMT1, but the wild-type strain outcompeted
GMT1i at a later time point at all sites of the respiratory tract, suggesting that the Bvgi phase does not serve
as a phenotypic phase specialized in colonization. Finally, even though B. pertussis expresses in vitro the Bvgi
phase at the human nasal temperature, anti-BipA antibodies were undetectable in a large collection of sera
from pertussis patients.
In his 1960 landmark article, B. W. Lacey reported that the
etiological agent of whooping cough, Bordetella pertussis, was
able to undergo profound phenotypic and antigenic alterations
in response to changes in growth temperature or as a result of
the addition of certain ions to the culture medium. After a
methodical and thorough analysis, he identified three antigeni-
cally distinct phases, which he designated X mode, I mode and
C mode, and coined the term antigenic modulation to define
the transition (entirely reversible) leading from X mode
through I mode to C mode (21). In the same report, he accu-
rately anticipated that “modulation in B. pertussis is not a
saltative change but a process of continuous change leading at
equilibrium to one of an infinite number of antigenic states.”
Some 25 years later, the locus governing this sophisticated
transition was identified, cloned (34, 37), and found to encode
a two-component regulatory system which was designated
BvgAS (formerly vir) (3, 35). The BvgAS signaling pathway
uses a complex four-step His-Asp-His-Asp phosphotransfer
mechanism involving three domains located in the sensor com-
ponent of the system (BvgS) and a fourth domain, a second
receiver, located in the response regulator of the system
(BvgA; for a review, see reference 7). Once phosphorylated,
BvgA has increased affinity for Bvg-activated promoters and
can also function as a repressor depending on the location of
the BvgA-P binding sites within the promoter. In addition,
each Bvg-activated promoter requires a specific level of
BvgA-P to achieve its maximum transcriptional activity.
Initially, BvgAS was considered to mediate a biphasic tran-
sition between a virulent phase, the Bvg phase (equivalent to
X mode in Lacey’s terminology), and an avirulent phase, the
Bvg phase (corresponding to Lacey’s C mode). At the mo-
lecular level, the Bvg phase is characterized by the expression
of the vast majority of virulence factors including all the known
adhesins and proteinaceous toxins which are encoded by the
so-called vir activated genes (vags). Conversely, the Bvg phase
is defined by the lack of activation of the vags, as well as by the
cessation of repression (mediated by the product of the bvgR
locus) (25, 26) of the so-called vir-repressed genes (vrgs) en-
coding outer membrane proteins of unknown function (20, 32).
All these molecular events translate into macroscopically
detectable differences between B. pertussis cultures growing on
solid medium supplemented with blood and thus, the Bvg
phase colonies are small, domed (hemispheric), and hemolytic
and the Bvg-phase colonies are large, flat, and nonhemolytic.
While B. pertussis expresses the Bvg phase when growing at
37°C in the absence of certain ions, including magnesium sul-
fate and nicotinic acid (modulators), incubation below 30°C or
addition of an appropriate amount of modulators to the cul-
ture medium brings about the transition to the Bvg phase. In
marked contrast with these two phenotypic phases, the third
phenotypic state reported by Lacey in Bordetella remained
virtually forgotten for almost 40 years.
Instrumental in reviving the interest on this intermediate
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phase was the discovery of a spontaneous mutant of a closely
related member of the Bordetella genus (B. bronchiseptica
RB53i) displaying in vivo and in vitro phenotypes (pathogenic
potential and ability to survive under nutrient-limiting condi-
tions, respectively) intermediate between those characteristic
of the Bvg and Bvg phases (11). Subsequent genetic analy-
ses revealed that, besides the constitutive mutation (bvgS-C3)
which was already present in the chromosome of RB53 and
makes this strain insensitive to modulation, RB53i carried an-
other point mutation in its bvgS gene. This second mutation
was found to result in a single-amino-acid substitution of four
residues C-terminal to the BvgS primary site of autophosphor-
ylation. When this point mutation (called bvgS-I1) was intro-
duced into wild-type B. bronchiseptica, the resultant strain
(RB50i) displayed an antigenic profile as well as a colony
morphology and hemolytic activity under nonmodulating con-
ditions indistinguishable from that of a semimodulated Borde-
tella culture (11). Therefore, the phenotypic state stably ex-
pressed by RB53i or displayed by an unmodulated culture of
RB50i was seemingly equivalent to that termed I mode by
Lacey and was subsequently designated the Bvgi phase.
At the molecular level, the Bvgi phase was characterized by
the absence of Bvg-repressed phenotypes and by the expres-
sion of a subset of vags corresponding to those not requiring
full (Bvg phase) levels of BvgA-P for their transcription
(known as class 2 genes; see reference 7). However, the most
prominent feature of the Bvgi-phase antigenic profile was the
expression of Bvgi-phase-specific polypeptides (Bips), whose
existence was also deduced by Lacey. Further studies led to the
identification of bipA, the first Bvgi-phase-specific gene, the
characterization of the bipA gene product, BipA (36), and the
study of the mechanism by which BvgAS controls the expres-
sion of bipA (12).
Whereas the open reading frame of B. bronchiseptica bipA is
predicted to encode a 1,578-amino-acid protein, the equivalent
B. pertussis open reading frame (29) code for a 1,308-amino-
acid protein. Both gene products exhibit homology to intimin
and invasin at their N termini, and B. bronchiseptica BipA has
been shown to be exposed on the cell surface (36). In addition,
polypeptides cross-reacting with B. bronchiseptica BipA have
been detected in lysates obtained from several B. pertussis
strains (14, 36) but not from human strains of B. parapertussis
(14). However, the role of the Bvgi phase in the life cycle of B.
bronchiseptica and the potential contribution of BipA to its
pathogenicity are still unclear. Thus, a B. bronchiseptica bipA
deletion mutant did not show any detectable colonization de-
fect in the context of a natural model of pathogen-host inter-
action (36), although additional unpublished evidence (8) sup-
ports the hypothesis that the Bvgi phase of B. bronchiseptica
may be necessary for transmission between hosts. In contrast,
there is an almost complete void of information regarding the
potential role of the Bvgi phase of B. pertussis during the
experimental respiratory infection. This fact prompted the in-
vestigation presented in this work.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The bacterial strains used in this
study are listed in Table 1. All the Bordetella strains were grown on Bordet-
Gengou (BBL) agar plates supplemented with either 15% or 7.5% defibrinated
sheep blood (Oxoid, Basingstoke, United Kingdom) for B. pertussis and B.
bronchiseptica, respectively. Plates were incubated at 37°C in loosely fitted jars
for 96 h (for B. pertussis) or 48 h (for B. bronchiseptica). To ensure absence of
Bvg-phase mutants in cultures, an aliquot of each culture was plated on BG-
blood agar, incubated for the appropriate time, and colonies were visually in-
spected for hemolytic activity.
When it was necessary to grow Bordetella under Bvg-phase (modulating)
conditions, nicotinic acid was added to the medium at a final concentration of 16
mM. Whole-cell lysates for sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis (PAGE) analysis were prepared from cells grown on BG-blood
agar.
Escherichia coli strains were grown in LB medium. When necessary, culture
media were supplemented with the appropriate combinations of the following
antibiotics: nalidixic acid (50 g/ml), kanamycin (50 g/ml), ampicillin (100
g/ml), gentamicin (20 g/ml), streptomycin (20 g/ml), and cephalexin (10
g/ml).
Construction of mutant strains by allelic exchange. The plasmids used in this
study are listed in Table 1. GMT1i and BPC1i were constructed via allelic
exchange by introducing the bvgS-I1-mutation carried by the plasmid pGMT65 in
a 988-bp EcoRI-BamHI fragment into the chromosomes of GMT1 and BPC1,
respectively. The mutated fragment was generated by overlapping PCR (4, 38)
with genomic DNA from B. pertussis GMT1 as the DNA template. The two DNA
segments necessary for this reaction were generated in two independent PCRs
with the following oligonucleotides: bvgi-1 (5-GCT GGA ATT CAT GCG CGT
GCT CA-3) and bvgi-2 (5-GCG TTC ATC GGC ATG CGG ATC TCG TG-3)
for the first PCR, and bvgi-3 (5-CAC GAG ATC CGC ATG CCG ATG AAC
GC-3) and bvgi-4 (5-CGG GAT CCT GCC ACC CAC TTG CGA GA-3) for
the second. These oligonucleotides (purchased from Life Technologies, Gibco
BRL, Grand Island, N.Y.) were designed to anneal at positions 2557, 3003, 3523,
and 3502, respectively, of the published bvgAS sequence of B. pertussis 165
(GenBank accession number M25401). Note both that primers bvgi-1 and bvgi-4
were engineered to include an EcoRI and a BamHI site, respectively, at their 5
end and that primers bvgi-2 and bvgi-3 incorporate the bvgS-I1 point mutation in
their sequence.
The 988-bp fragment containing the bvgS-I1 mutation was generated in a new
PCR with oligonucleotides bvgi-1 and bvgi-4 in the presence of a 1:1 molar ratio
of the two previously amplified fragments. The resultant PCR product was cut
with EcoRI and BamHI and ligated to EcoRI- and BamHI-digested pEGBR to
generate pGMT65. DNA sequencing of the PCR-generated segment confirmed
that no other alterations besides the bvgS-I1 mutation were present in this
plasmid. pGMT65 was mobilized from E. coli SM10 into B. pertussis GMT1 and
BPC1 by conjugation. Exconjugants were selected on BG-blood agar supple-
mented with Gm and then grown on BG-blood agar without antibiotic selection
to allow for the loss of the plasmid. Plasmid-cured clones were selected on
BG-blood agar supplemented with 5% sucrose. Clones in which the allelic re-
placement had occurred as intended were readily detected by their phenotypic
characteristics (see below).
Attempts to construct derivatives of B. pertussis carrying in-frame deletions in
bipA by allelic exchange with the sucrose counterselection method were repeat-
edly unsuccessful since, for unknown reasons, all the selected exconjugants un-
expectedly displayed a total insensitivity to sucrose. Mutant strains GMT1-DBA,
GMT1i-DBA, and GG2-DBA were finally constructed by allelic exchange with
pSS1129-based plasmids and an alternative counterselection method already
described (33). As parental strains for these constructions, spontaneous nalidixic
acid-resistant mutants of GMT1, GMT1i, and GG2 (GMT1-Nal, GMT1i-Nal,
and GG2-Nal, respectively) were used.
The0.6-kb DNA fragment carrying the bipA deletion allele was generated by
overlapping PCR (4, 38) with genomic DNA from B. pertussis GMT1 as the DNA
template. In this fragment, the deletion junction is flanked by two 0.3-kb
segments; the one 5 to the deletion encompasses the first 37 codons of the bipA
ORF as well as 162 bp upstream the BipA start codon, whereas the portion 3 to
the deletion includes the last 55 codons of the bipA open reading frame and
210-bp downstream of the BipA stop codon. This mutation results in the loss of
the 93% of the bipA open reading frame. The fragments upstream and down-
stream of the deletion junction were generated in two independent PCRs with
oligonucleotides bipA-1 (5-CCT GTG GCC GGA GAG ATG TA-3) and
bipA-2 (5-GGT TCT GGC GAC GCG GGC T-3) to generate the bipA 5
end-containing fragment, and bipA-3 (5-AGC CCG CGT CGC CAG AAC
CCG CCG GGC CGT GAT TGC-3) and bipA-4 (5-CGC CGC ATC CAT
CGC CGT-3) to generate the corresponding 3 portion. These oligonucleotides
(purchased from Genset Oligos, Paris, France) were designed to anneal at
positions 1164465, 1164738, 1168389, and 1168764, respectively, of the published
B. pertussis Tohama I chromosome sequence (29) (GenBank accession number
NC_002929). Note the presence of the deletion allele in the sequence of primer
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bipA-3 as well as the complementarity exhibited by primers bipA-2 and bipA-3
over a long stretch of nucleotides.
The 0.6-kb fragment containing the deletion allele was generated in a new
PCR with oligonucleotides bvgi-1 and bvgi-4 in the presence of a 1:1 molar ratio
of the two previously amplified fragments. The Taq-amplified PCR product was
directly ligated into 3-T overhangs of pCR2.1 to construct pNur5 and then the
0.6-kb BamHI-XbaI fragment of this plasmid containing the bipA deletion
allele was ligated to BamHI- and NheI-digested pSS1129 to generate pNur8. The
0.6-kb PCR-generated DNA fragment was sequenced to confirm that the bipA
open reading frame had been maintained. pNur8 was mobilized from E. coli
SM10 into B. pertussis GMT1, GMT1i, and GG2 by conjugation. Exconjugants
were selected on BG-blood agar supplemented with nalidixic acid and gentami-
cin (streptomycin cannot be used as exconjugants become streptomycin sensi-
tive) and then grown on BG-blood agar without antibiotic selection to allow for
the loss of the plasmid. Plasmid-cured clones were selected on BG-blood agar
supplemented with streptomycin, and clones in which the genetic rearrangement
had occurred as intended were identified by PCR with primers bipA-1 and
bipA-4.
BPC1 was constructed by allelic exchange with plasmid pJM503 (28) and the
method described for the construction of GMT1-DBA. Likewise, the Bvg-
phase-locked mutant GG2 was constructed with the same allelic exchange pro-
cedure, resulting in an in-frame deletion of a 233-bp XcmI fragment of bvgA in
B. pertussis strain GMT1 (Gordon and Cotter, unpublished results).
To use as controls throughout the study, strains essentially identical to B.
bronchiseptica RB50i and RB53i were constructed via allelic exchange by intro-
ducing the bvgS-I1 mutation carried by the plasmid pEG129 into the chromo-
somes of RB50 and RB53, respectively, as described by Cotter and Miller (11).
Construction of strains carrying lacZ fusions to B. pertussis bipA and quanti-
tation of -galactosidase activity. A 595-bp DNA fragment internal to bipA was
generated by PCR with genomic DNA from B. pertussis GMT1 as template and
oligonucleotides (Genset Oligos) bipA-5 (5-GCG AAT TCT GGT GGG CGG
CAG CAT CC-3) and bipA-6 (5-GCG GAT CCA GCG GCG CAT ACA CAT
T-3), engineered to incorporate EcoRI and BamHI sites, respectively, at their 5
ends. These oligonucleotides were designed to anneal at positions 1164768 and
1165363, respectively, of the published B. pertussis Tohama I chromosome se-
quence (29) (GenBank accession number NC_002929). The PCR product was
digested with EcoRI and BamHI and cloned into EcoRI- and BamHI-digested
pEGZ (i.e., upstream of the promoterless lacZ gene) to generate pNur2. This
plasmid was transformed into competent E. coli DH5 cells and mobilized into
B. pertussis GMT1, GMT1i, and GG2 by triparental conjugation with the tra
functions provided by plasmid pBRK2013. Exconjugants were selected on BG-
blood agar supplemented with gentamicin. -Galactosidase activity was mea-
sured as already described (24) in cells grown in BG-blood agar for 72 h. To
detect the occurrence of spontaneous bvgAS mutants, aliquots of each test
suspension were plated onto BG-blood agar. The statistical significance of dif-
ferences in expression was determined by two-tailed Student’s t test comparisons.
TABLE 1. Strains and plasmids used in this study
Strain or plasmid Relevant featuresa Source or reference
B. bronchiseptica
RB50 Wild type, Smr 10
RB53 bvgS-C3, Bvg-phase-locked derivative of RB50 10
RB50i bvgS-I1-carrying derivative of RB50, unable to express the Bvg phase 11; this work
RB50i-BAL RB50i::pNur2; chromosomal bipA-lacZ fusion This work
RB53i bvgS-C3, bvgS-I1, Bvgi-phase-locked derivative of RB50 11; this work
B. pertussis
GG Wild type, clinical isolate This work
GMT1 Spontaneous Smr derivative of GG 24
GMT1 Nalr Spontaneous Nalr derivative of GMT1 This work
GMT1i bvgS-I1-carrying derivative of GMT1, unable to express the Bvg phase, Smr This work
GMT1i Nalr Spontaneous Nalr derivative of GMT1i This work
BPC1 bvgS-C3, Bvg-phase-locked derivative of GMT1, Smr This work
BPC1i bvgS-C3, bvgS-I1, Bvgi-phase-locked derivative of GMT1, Smr This work
GMT1-BAL GMT1::pNur2; chromosomal bipA-lacZ fusion, Gmr This work
GMT1i-BAL GMT1i::pNur2; chromosomal bipA-lacZ fusion, Gmr This work
GG2-BAL GG2::pNur2; chromosomal bipA-lacZ fusion, Gmr This work
GG2 bvgA, Bvg-phase-locked derivative of GMT1 This work
GG2 Nalr Spontaneous Nalr mutant derivative of GG2 This work
GMT1-DBA GMT1 Nalr bipA, Smr This work
GMT1i-DBA GMT1i Nalr bipA, Smr This work
GG2-DBA GG2 Nalr bipA, Smr This work
Tohama 1 Wild type 19
E. coli
SM10 (	 pir) thi-1 thr leu tonA lacY supE rec::RP4-2-Tet::Mu, Knr 	 pir 31
DH5 F hsdR17 supE44 thi-1 recA1 gyrA (argF-lac) U169 
 80dlacZM15 RP4-2-TcMu Knr Stratagene
Top 10 F FlacIq Tn 10 (Tetr) mcrA (mrr-hsdRMS-mcrBC) 
80lacZM15 lacX74 recA1alaD139
(ara-leu)7697 galU galK rpsL endA1 nupG
Invitrogen
Plasmids
pBRK2013 Helper plasmid for triparental matings, oriTIncP tra oriE1 Kn
r 13
pEGZ Suicide plasmid for the construction of lacZ transcripcional fusions, Gmr, Apr, oriTIncP 24
pEGBR sacBR-carrying derivative of pSS1129; Knr, Apr, Sucs, oriTIncP 1
pEG129 pSS1129 derivative carrying a 0.9-kb EcoRl-BbrPl fragment from RB53i bvgS 11
pNur2 pEGZ derivative carrying a 595-bp internal fragment of B. pertussis bipA cloned into
EcoRI-BamHI site
This work
pNur5 630-bp B. pertussis bipA deletion allele generated by PCR and cloned into pCR2.1 This work
pNur8 BamHI-Xbal fragment from pNur5 cloned into the BamHI and NheI sites of pSS1129 This work
pGMT65 988-bp EcoRI-BamHI fragment from B. pertussis GMT1 containing the bvgS-I1
mutation generated by overlapping PCR and cloned into the EcoRI-BamHI sites of
pEGBR
This work
pSS1129 Allelic exchange vector, Gmr Apr, rpsL oriTIncp 35
pCR 2.1 Cloning vector Invitrogen
a Sm, streptomycin; Nal, nalidixic acid; Gm, gentamicin; Kn, kanamycin; Ap, ampicillin; Suc, sucrose.
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SDS-PAGE and Western immunoblotting. SDS-PAGE and Western immu-
noblotting were performed as previously described (22, 24). Briefly, bacterial
cells suspended in phosphate-buffered saline (PBS) were lysed by addition of 2
SDS-PAGE sample buffer (30). Bacterial lysates were boiled for 5 min, stacked
in an SDS–4% polyacrylamide gel and separated in an SDS–7.5% polyacryl-
amide gel. Proteins were transferred to either polyvinylidene difluoride or nitro-
cellulose membranes for immunoblotting. Membranes were incubated with a
1:1,000 dilution of one of the following primary antibodies: serum from a rat
infected with B. bronchiseptica RB53i (antiserum S3), serum from a rat hyper-
immunized with killed whole B. pertussis GMT1i cells (antiserum S219), or sera
from patients convalescing from pertussis. Antigen-antibody complexes were
detected with a 1:5,000 dilution of horseradish peroxidase-conjugated antibody
of the appropriate specificity (Amersham International, Little Chalfont, United
Kingdom) and visualized by an enhanced chemiluminescence technique (Amer-
sham) according to the manufacturer’s instructions.
Experimental animals. Experimental intranasal inoculations of mice with B.
pertussis were performed as previously described (23). Briefly, female BALB/c
mice were obtained from Harlan Spain (Harlan Interfauna Iberica S.A., Barce-
lona, Spain) at 3 weeks of age. To confirm that they were Bordetella-free, two
animals of each lot were euthanized, and samples of nasal, tracheal, and lung
tissue were removed and cultured on BG-blood agar. Inocula were prepared
from B. pertussis cells grown on BG-blood agar for 3 days and consisted of 106
CFU administered intranasally in 50 l of PBS while the animals were slightly
anesthetized by halothane inhalation. Each experimental group consisted of at
least three mice (for time point zero) or at least five mice (for time point 8 days).
At each experimental time point, mice were anesthetized by halothane inha-
lation, a sample of blood was obtained, and then the animals were sacrificed by
cervical dislocation. The chest cavity was opened, and approximately 0.5 cm of
trachea and the right lung lobe were removed and placed in PBS for homoge-
nization. The nose was dissected, and the entire nasal septum and adjacent
tissues were removed and placed in PBS. Tissues were homogenized with tissue
grinders, and aliquots of the suspensions were plated on BG-blood agar for
viable count. The lower limits of detection for these counts were 4 CFU for both
the nasal and tracheal samples and 50 CFU (5,000 in some experiments) for the
lung samples. Viable counts below the lower limit of detection were arbitrarily
assigned to half the lower limit of detection for each assay.
In all the animal experiments except for the respiratory mixed infections,
statistical significance was determined by two-way analysis of variance, and when
interaction was found to be significant, the means were compared with contrasts.
For the respiratory mixed infection of mice with GMT1 and GMT1i, an identical
experimental protocol was followed, although, in this case, the inoculum con-
sisted of 106 CFU of each bacterial strain suspended in a final volume of 50 l
of PBS. To ensure that equal numbers of CFU for each strain had been delivered
to the animals, appropriate dilutions of the inocula were plated on BG-blood
agar for viable count. The two colonial types recovered from the animals were
easily identified as formed by GMT1 or GMT1i by visually inspecting their
distinct morphology and hemolytic activity. For these mixed infections, the dif-
ferences in colonization both in the trachea and in the lungs were analyzed by the
Wilcoxon signed rank test (due to the existence of a significant number of values
falling below the lower limit of detection), whereas for the nasal septum a mixed
factorial analysis of variance, with a between-subjects factor (time) and a within-
subjects factor (strains), was used. All the statistical analyses were performed
with SPSS software (SPSS 11.0 for Windows; SPSS Inc., Chicago, Ill.).
Intranasal inoculation of a Bordetella-free 3-week-old female Wistar rat (Har-
lan Interfauna Iberica S.A., Barcelona, Spain) with B. bronchiseptica RB53i was
performed by placing a 10-l drop of PBS containing 200 CFU of RB53i into one
nostril as already described (24). The rat immune serum (antiserum S3) was
obtained 3 weeks after the inoculation.
To obtain an antiserum against the Bvgi phase of B. pertussis GMT1i (anti-
serum S219), a 4-week-old Bordetella-free Wistar rat was inoculated intraperi-
toneally with 109 killed whole cells of B. pertussis GMT1i suspended in 200 l of
PBS, essentially as previously described (32). Briefly, GMT1i cells grown on
BG-blood agar for 3 days were washed once with saline, and the optical density
at 540 nm of the suspension was then adjusted with saline to 0.12 (109 CFU/ml,
approximately). Bacterial cells were killed by adding merthiolate and erythro-
mycin to the suspensions, both at a final concentration of 0.01% (wt/vol), and by
incubating the resultant mixture at 37°C for 3 h. This treatment killed 100% of
the sampled cells as assessed by viable counting of the treated suspension on BG
plates. Prior to each inoculation, whole cells were washed twice with saline.
Three weeks after the primary immunization, the animal received by the same
route a second dose of freshly prepared inoculum containing this time 107 killed
cells of GMT1i. The immune antiserum was collected 2 weeks after the second-
ary immunization.
All the animal protocols used in this study were approved by the University of
Navarra Animal Research Committee (protocol number 039/00).
PCR, cloning, and sequencing. PCRs were performed with the following
conditions: 3 mM MgCl2, 5% dimethyl sulfoxide, 1 U of Taq polymerase
(PerkinElmer, Wellesley, Mass.), 250 M each of the four deoxynucleoside
triphosphates, and 20 pmol of each primer were combined and brought to a total
volume of 25 l. As the source of template DNA, a small portion of a colony was
resuspended in the solution. A Perkin-Elmer GeneAmp 2400 thermal cycler was
used for the reactions. The cycling parameters were incubation at 95°C for 5 min,
followed by 30 cycles of 95°C for 1 min, 55°C for 1 min, and 72°C for 1 min, and
a final incubation at 72°C for 5 min. PCR products were cloned into the pCR2.1
vector with the TA cloning kit (Invitrogen, Carlsbad, Calif.) according to the
manufacturer’s instructions. Plasmids containing the cloned PCR products were
submitted for sequencing to Sistemas Genomicos, S.L. (Paterna, Spain).
RESULTS
Construction and phenotypic characterization of B. pertussis
Bvgi-phase mutants. In B. bronchiseptica it was previously
shown that the presence of the bvgS-I1 mutation leads to the
expression of the Bvgi phase under growth conditions that
would otherwise promote growth in the Bvg phase (11). How-
ever, the bvgS-I1-carrying derivative of strain RB50, designated
RB50i, was not totally locked in the Bvgi phase but still re-
tained its capacity to modulate to the Bvg phase when grown
under fully modulating (Bvg-phase) conditions. To determine
whether B. pertussis can stably display an equivalent pheno-
type, we introduced by allelic exchange the bvgS-I1 point mu-
tation into the chromosome of wild-type B. pertussis GMT1,
generating strain GMT1i.
Unlike the wild-type strain, though similar to the behavior
described for RB50i, when GMT1i was grown under non-
modulating (Bvg-phase) conditions, it gave rise to colonies
whose morphology and hemolysis were intermediate between
those of the Bvg and Bvg phases (i.e., Bvgi-phase-like col-
onies). However, GMT1i behaved like the wild-type strain
when grown under other conditions, rendering Bvgi-phase-like
colonies and Bvg-phase-like colonies when grown under
semimodulating (3 mM nicotinic acid) or fully modulating (16
mM nicotinic acid) conditions, respectively (data not shown).
This result suggests that, as shown in the equivalent B. bron-
chiseptica mutant, the single-amino-acid substitution carried by
the BvgAS system of GMT1i alters the phosphorylation cas-
cade in a way such that only intermediate amounts of BvgA-P
are produced even under nonmodulating (Bvg-phase) condi-
tions.
To construct a B. pertussis mutant expressing the Bvgi phase
under any growth conditions, we introduced the bvgS-I1 mu-
tation into strain BPC1, a B. pertussis GMT1 derivative carry-
ing the bvgS-C3 mutation. The resultant mutant strain was
designated BPC1i and, as expected, gave rise to Bvgi-phase-
like colonies when grown under Bvg and Bvg-phase condi-
tions (data not shown). GMT1i and BPC1i retained their phe-
notype after repeated passes on BG-blood agar, and neither of
them were prone to revert to the wild-type phenotype or
showed an increase in the rate of phase variation (irreversible
transition to the Bvg phase) compared to the corresponding
isogenic parental strain.
Comparative analysis of bipA transcriptional activity in
GMT1, GMT1i, and a Bvg-phase-locked isogenic mutant. To
study the role of the Bvgi phase of B. pertussis, we first sought
to characterize in detail the pattern of Bvg-dependent regula-
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tion of bipA, the only gene hitherto reported in a wild-type
strain of a closely related member of the Bordetella genus, B.
bronchiseptica, to be upregulated under semimodulating con-
ditions (12). For this purpose, we constructed derivatives of
GMT1, GMT1i, and GG2 (an isogenic Bvg-phase-locked mu-
tant of GMT1; see Table 1) carrying chromosomal bipA-lacZ
transcriptional fusions and measured the production of -ga-
lactosidase in the resultant strains, termed GMT1-BAL,
GMT1i-BAL, and GG2-BAL, respectively.
As shown in Fig. 1, growth of GMT1-BAL under semimo-
dulating conditions (2.5 to 5 mM nicotinic acid) resulted in a
four- to fivefold increase in bipA transcription with respect to
levels measured in cells from the same strain grown under
Bvg or Bvg-phase conditions. These differences were found
to be highly significant (P 0.001). However, this physiological
upregulation of bipA was dwarfed by that detected in the bvgS-
I1-carrying derivative of GMT1-BAL, GMT1i-BAL, grown un-
der nonmodulating conditions (25-fold with respect to the
level measured in unmodulated cells of GMT1-BAL). The
difference in bipA transcriptional activity (6-fold) between
GMT1i and GMT1 grown under semimodulating conditions (P
 0.001) suggests that addition of submodulating amounts of
nicotinic acid does not suffice to recreate a full Bvgi-phase
status in the wild-type strain, thus resembling the behavior
reported to occur with a Bvg-phase-specific phenotype (frl
expression) in a B. bronchiseptica Bvg-phase-locked mutant
(11). In sharp contrast with the previous observation, transcrip-
tional activity of bipA was almost undetectable in the isogenic
Bvg-phase-locked mutant of GMT1-BAL (GG2-BAL).
These results complement and confirm those obtained by
Fuchslocher and collaborators (14) with a similar experimental
design and the same B. pertussis Bvgi mutant whose construc-
tion we report in the present study (GMT1i).
Characterization of the expression profile of B. pertussis
Bvgi-phase-specific polypeptides cross-reacting with B. bron-
chiseptica Bvgi-phase-specific polypeptides. With an antibody
directed against the C terminus of B. bronchiseptica BipA,
Stockbauer and collaborators identified in cell lysates of B.
pertussis GMT1i two major cross-reacting bands of approxi-
mately 140 and 115 kDa that were absent in cells from Bvg
and Bvg-phase-locked derivatives (36). To expand this anal-
ysis, we obtained whole-cell extracts of GMT1 and of its iso-
genic Bvgi mutants (GMT1i and BPC1i) grown with various
concentrations of nicotinic acid and analyzed them side by side
by Western blot with serum from a rat infected with B. bron-
chiseptica RB53i (antiserum S3). As shown in Fig. 2A, anti-
serum S3 detected the presence of a type of polypeptides that
was present in all the lysates irrespective of their modulation
status and therefore can be classified as Bvg-independent
polypeptides (stars in Fig. 2A). In contrast, a second set of
bands were undetectable under both Bvg-phase and Bvg-
phase conditions (0 and 16 mM nicotinic acid, respectively),
thus being exclusively expressed by B. pertussis GMT1 when
FIG. 1. Quantification of B. pertussis bipA transcriptional activity under various growth conditions. The bipA-lacZ fusion-carrying derivatives of
B. pertussis GMT1, GMT1i, and GG2 (GMT1-BAL, GMT1i-BAL, and GG2-BAL, respectively) were grown under Bvg-phase conditions (0 mM
nicotinic acid), and levels of -galactosidase were quantitated as specified in the Materials and Methods section and expressed as -galactosidase
units. In other experiments, GMT1-BAL was grown in the presence of the indicated amount of nicotinic acid. In preliminary tests, these
concentrations were found to induce the highest level of BipA expression. Results are the average of three independent experiments performed
in triplicate. Error bars represent the means  1 standard deviation. The asterisks denote a statistically significant difference (, P  0.01; ,
P  0.001) between the two specified groups.
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growing under semimodulating conditions (i.e., 3.2 and 5 mM
nicotinic acid; arrows in Fig. 2A).
These polypeptides consisted of a major band of 140 kDa
and two minor bands of approximately 100 and 115 kDa. In
view of the molecular mass of the deduced B. pertussis BipA
gene product (137 kDa; GenBank accession number
NC_002929-BP1112) (29) and of the aforementioned results
by Stockbauer et al., it is likely that the slowest-running
polypeptide could correspond to the B. pertussis BipA ho-
molog. Consistent with this hypothesis, the range of expression
of the 140-kDa polypeptide as a function of the concentra-
tion of nicotinic acid (Fig. 2A) nearly correlated with the range
of bipA transcriptional activity shown in Fig. 1.
These results demonstrate that the expression of Bvgi-phase
polypeptides in B. pertussis (and presumably the rest of Bvgi-
phase-specific phenotypes) can be induced by growing the
wild-type strain in the presence of levels of a chemical modu-
lator somewhat intermediate (e.g., 3.2 mM and 5 mM nicotinic
acid in Fig. 2A) between those leading to growth in the Bvg
phase (0 mM) or in the Bvg phase (16 mM). Interestingly,
Fig. 2 also shows that this conclusion holds strictly true when,
instead of a chemical modulator, a physical modulator poten-
tially having a more relevant physiological role (temperature)
is used. Thus, production of Bvgi-phase polypeptides could
only be detected in GMT1 when this strain was incubated at
temperatures intermediate (i.e., 30°C in Fig. 2B) between
those leading to growth in the Bvg and Bvg phases (37°C
and 26°C, respectively). In addition and regardless the type of
modulator used, the profile of Bvgi-phase polypeptides ex-
pressed by GMT1 matched that of its isogenic Bvgi-phase mu-
tant (BPC1i), as shown both in Fig. 2A and 2B.
Finally, results shown in Fig. 2A confirm that, although
GMT1i displays the most characteristic marker of the Bvgi-
phase (expression of Bvgi-phase polypeptides) when grown
under Bvg or Bvgi-phase conditions, it still retains its capacity
to gradually modulate to the Bvg phase when increasing
amounts of nicotinic acid are added to the culture medium.
Thus, expression of Bvgi-phase polypeptides dropped to unde-
tectable levels when GMT1i was grown in the presence of 16
mM nicotinic acid. On the contrary, these modulating condi-
tions not only failed to downregulate Bvgi-phase polypeptide
expression in BPC1i (as expected of a mutant stably locked in
the Bvgi phase) but, for unknown reasons, induced the expres-
sion of levels of Bvgi-phase polypeptides noticeably higher
than those measured in cells of the same strain grown under
Bvg-phase conditions.
Construction and phenotypic characterization of bipA
strains of B. pertussis. Stockbauer and collaborators showed
that all the Bvgi-phase-specific polypeptides detected in B.
bronchiseptica RB50i cell lysates by an antiserum of the same
specificity as antiserum S3 are most probably BipA breakdown
products since inactivation of bipA in RB50i brings about the
loss of the entire Bvgi-phase-specific reactivity (36). To study
the contribution of BipA to the Bvgi-phase-specific antigenic
profile of B. pertussis, we analyzed BipA expression in a B.
pertussis bipA mutant. For this purpose, we first made use of
the bipA-lacZ fusion-carrying derivative of GMT1i (GMT1i-
BAL) since the insertion of the DNA segment internal to bipA
and transcriptionally fused to the lacZ gene should result in the
inactivation of bipA in this mutant.
Lysates of GMT1i and GMT1i-BAL were separated by SDS-
PAGE, transferred to polyvinylidene difluoride and probed
with antiserum S3. As shown in Fig. 3A, none of the Bvgi-
phase-specific polypeptides expressed by GMT1i was detected
in the lysate of the B. pertussis bipA mutant. As a control, the
same bipA-lacZ fusion was introduced by homologous recom-
bination into the chromosome of B. bronchiseptica RB50i to
construct RB50i-BAL. In agreement with published observa-
tions (36) and similar to the results obtained with the equiva-
lent B. pertussis strains (Fig. 3A), disruption of bipA in RB50i-
FIG. 2. Western blot analysis of B. pertussis Bvgi-phase-specific polypeptides expressed under different modulating conditions. (A) Whole-cell
extracts of B. pertussis GMT1, GMT1i, BPC1i, and GG2 grown with the indicated concentration of nicotinic acid were separated by SDS-PAGE,
transferred to polyvinylidene difluoride, and probed with antiserum S3. (B) Whole-cell extracts of B. pertussis GMT1 or BPC1i grown at various
temperatures (26, 30, or 37°C for GMT1; 37°C for BPC1i) were separated by SDS-PAGE, transferred to polyvinylidene difluoride, and probed with
antiserum S3. Arrows and stars show Bvgi-phase-specific polypeptides and Bvg-independent polypeptides, respectively. The positions of molecular
size markers are indicated on the left (in kilodaltons).
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BAL abolished all the Bvgi-phase-specific reactivity detected
by antiserum S3 in its parental strain (RB50i; data not shown).
However, since this phenomenon could also be due to unin-
tended polar effects caused by the insertion of the plasmid on
genes downstream of bipA and transcriptionally linked to it, we
constructed by allelic exchange a GMT1i derivative carrying an
in-frame deletion in bipA and designated it GMT1i-DBA.
As shown in Fig. 3B, Western blot analysis of GMT1i-DBA
with S3 antiserum revealed that this mutant did not express any
of the three major Bvgi-phase-specific polypeptides and that its
antigenic pattern was indistinguishable from that of the wild-
type strain grown under Bvg-phase conditions. These results
indicate that, similar to B. bronchiseptica, the fast-running
(100-kDa and 115-kDa in B. pertussis) Bvgi-phase-specific
polypeptides are in all likelihood BipA breakdown products
and therefore BipA seems to be the only B. pertussis Bvgi-
phase-specific antigen detectable by serum from a rat infected
with a B. bronchiseptica Bvgi-phase-locked mutant. Neverthe-
less, it cannot be excluded that the appropriate expression of
the 100-kDa and 115-kDa polypeptides may depend on the
presence of a wild-type bipA allele and/or a functional BipA
protein.
Search for B. pertussis Bvgi-phase-specific antigens other
than BipA. To determine whether B. pertussis possesses an
exclusive set of Bvgi-phase-specific antigens not shared with B.
bronchiseptica, we first compared the antigenic profile of a B.
pertussis Bvgi-phase-locked mutant (BPC1i) with that of its
equivalent B. bronchiseptica mutant (RB53i) by Western im-
munoblot with sera from mice infected with B. pertussis GMT1i
for 20 days. Not surprisingly, due to the poor antibody re-
sponse elicited by B. pertussis when used to infect mice by the
intranasal route (15), none of the tested sera showed a signif-
icant reactivity against any of the cell extracts (data not shown).
To circumvent this problem, we instead raised an antiserum
against the Bvgi phase of B. pertussis by immunizing a rat by the
intraperitoneal route with suspensions containing killed whole
cells of GMT1i. This immune serum was designated antiserum
S219. To be able to differentiate the anti-BipA-specific anti-
body response from that potentially directed against other
Bips, we analyzed side by side the antigenic profile of GMT1i
and that of its isogenic BipA deletion mutant (GMT1i-DBA)
by Western blot with antiserum S219. Intriguingly, although we
expected to detect an antibody response directed against a
rather wide variety of B. pertussis cell epitopes, a significant
part of the detectable reactivity was found to be directed
against Bvgi-phase-specific polypeptides (Fig. 4) and strongly
resembled that exhibited by antiserum S3 (see for example Fig.
3B). Similar to the results obtained with antiserum S3, inacti-
vation of bipA in GMT1i-DBA sufficed to abolish all the Bvgi-
phase-specific reactivity detected by antiserum S219 in GMT1i.
Our results demonstrate that, similar to B. bronchiseptica (11,
36), BipA behaves as the immunodominant Bvgi-phase-specific
antigen of B. pertussis, at least in rats immunized with killed
whole cells by the intraperitoneal route.
Ability of GMT1i to colonize and persist in the respiratory
tract of mice. To study whether expression of phases other than
the Bvg phase enables B. pertussis to colonize and persist in
vivo, we performed a comparative analysis of the pathogenic
potential of GMT1 and GMT1i in a mouse model of respira-
tory infection. To ensure delivery of large numbers of bacteria
to the entire respiratory tract, we inoculated groups of eight
FIG. 3. Western blot-based assessment of the presence of Bvgi-
phase-specific polypeptides other than BipA in B. pertussis. Whole-cell
extracts of the indicated strain of B. pertussis grown under Bvg-phase
conditions were separated by SDS-PAGE, transferred to polyvinyli-
dene difluoride, and probed with antiserum S3. In each panel, the
arrangement of the lanes is as follows: left lanes, wild-type strain;
middle lanes, bvgS-I1-carrying derivative; right lanes, bipA mutant con-
structed either by insertional activation of bipA (A) or by introduction
of an in-frame deletion in bipA (B). The positions of molecular size
markers are indicated on the left (in kilodaltons).
FIG. 4. Western blot-based assessment of the presence of Bvgi-
phase-specific polypeptides other than BipA and exclusive of B. per-
tussis. Whole-cell extracts of the indicated B. pertussis strains were
grown under Bvg-phase conditions, separated by SDS-PAGE, trans-
ferred to polyvinylidene difluoride, and probed with serum from a rat
immunized with killed whole cells of B. pertussis GMT1i (antiserum
S219). The positions of molecular size markers are indicated on the
left (in kilodaltons).
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mice intranasally with a high-volume, high-dose inoculum (50
l of PBS containing 106 CFU of the corresponding strain).
Approximately 1 h later we sacrificed three mice per group to
determine the initial level of colonization reached by GMT1
and GMT1i in the upper (nasal septum) and lower (trachea
and lungs) respiratory tract. These levels of colonization were
compared again in the remaining animals at day 8 postinocu-
lation, approximately coinciding with the peak of infection in
our experimental model. Since the virulence of GMT1 in a
mouse model of respiratory infection had never been subjected
to a side-to-side comparison with that of a well-characterized
B. pertussis strain, we also included in this analysis the proto-
type B. pertussis strain, Tohama I.
As shown in Fig. 5, while mice inoculated with GMT1i had
numbers of CFU at the beginning of the experiment (day 0)
comparable to those of mice inoculated with GMT1 at all the
sites of the respiratory tract, GMT1i showed a marked defect
in colonization in the lower respiratory tract of mice compared
to the wild-type strain at day 8 postinoculation. Specifically, the
numbers of CFU recovered from the trachea and the lungs of
animals infected with the wild-type strain were 100 and 10,000
times higher, respectively, than those obtained from mice in-
fected with its isogenic mutant lacking the capacity to express
the Bvg phase. These results, which resemble those obtained
with RB50i in a natural host of B. bronchiseptica, the rat (11),
demonstrate that Bvg phases of B. pertussis other than the
Bvg phase are not sufficient for the colonization of the lower
respiratory tract of mice.
Interestingly, the ability of GMT1i to colonize the nasal
septum of mice was indistinguishable from that of its parental
strain at day 8 postinoculation (Fig. 5). It is important to note
that, as we have previously shown with an identical animal
model (23), a Bvg-phase-locked mutant of B. pertussis is fully
impaired for the colonization of the entire respiratory tract of
mice and cannot even be recovered from the animal as early as
day 6 postinoculation. Therefore, these results indicate that the
Bvg phase of B. pertussis is not strictly necessary for the
colonization of the upper respiratory tract of mice, since a
strain devoid of this phase can colonize the nasal cavity at
wild-type levels. Finally, our results demonstrate that GMT1
exhibits an ability to colonize and persist in the mouse respi-
ratory tract similar to that of the B. pertussis prototype strain
Tohama I (Fig. 5).
Experimental respiratory mixed infection with GMT1 and
GMT1i. If the colonization defect exhibited by GMT1i in the
lower murine respiratory tract was due to an inability to ex-
press one or several Bvg-phase-specific factors at wild-type
levels, coinoculation of the mutant along with the wild-type
strain in a mixed respiratory infection could potentially restore
that defect. To test this hypothesis, we followed the experi-
mental design outlined in the previous section, but this time
the animals were inoculated with a mixed suspension of GMT1
and GMT1i (106 and 106 CFU) suspended in 50 l of PBS. As
shown in Fig. 6, the ability of GMT1 to colonize the murine
respiratory tract was not affected by concomitant infection with
GMT1i at any experimental time point since the wild-type
strain colonized all sites of the coinfected animals at levels
indistinguishable from those reached when administered un-
mixed (see Fig. 5 and two independent experiments [not
shown]).
In contrast, the presence of the wild-type strain not only
proved to be insufficient to restore the colonization defect
displayed by GMT1i but contributed to make it more pro-
nounced. Thus, unlike the behavior described in single-infec-
FIG. 5. Colonization of the mouse respiratory tract by wild-type
and mutant (bvgS-I1 carrying) B. pertussis strains. Groups of mice were
inoculated intranasally with 50 l of PBS containing 106 CFU of one
of the experimental strains (GMT1, GMT1i, and Tohama I). At days
0 (three mice at least) and 8 (five mice at least), the animals were
sacrificed, and colonization at various sites of the respiratory tract was
determined. Error bars represent 1 standard deviation. The dashed
line indicates the lower limit of detection. The asterisks denote a
statistically significant difference (, P  0.01; , P  0.001) be-
tween the two specified groups.
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tion experiments, GMT1i was recovered in lower numbers
than GMT1 (P  0.05) from the lungs of the animals at day 0.
These differences became much more prominent at day 8
postinoculation, when GMT1 outcompeted GMT1i not only,
as expected, in the lower respiratory tract (P  0.05), but also
in the upper respiratory tract (P  0.01). These results dem-
onstrate that the Bvg phase is better endowed than the Bvgi
phase for colonization of the upper murine respiratory tract,
although the latter phase can make up for the former in the
absence of competition between the two. In addition, our re-
sults confirm that the expression of the Bvg phase is abso-
lutely required, at least temporarily, for the colonization of the
lower respiratory tract. Finally, our observations indicate that
the virulence factors that enable GMT1 to reach wild-type
levels of colonization in the murine respiratory tract cannot be
exploited by its isogenic B. pertussis Bvgi mutant to restore its
colonization defect.
Assessment of the role of BipA in the pathogenesis of B.
pertussis. To determine whether BipA plays a role in the patho-
genicity of B. pertussis, we first constructed a mutant equivalent
to GMT1i-DBA (i.e., carrying an in-frame deletion in bipA) in
the wild-type strain (GMT1) background and designated it
GMT1-DBA. We then compared the ability of GMT1-DBA to
colonize and persist in the respiratory tract of mice with that of
GMT1 with the same experimental design of respiratory infec-
tion described above. As shown in Fig. 7A, GMT1-DBA was
found to be as capable as the wild-type strain to colonize all the
sites of the murine respiratory tract during the entire course of
the experiment. Our results are consistent with previous ob-
servations reporting that a B. bronchiseptica mutant carrying an
in-frame deletion in bipA was not defective for the colonization
of any site of the respiratory tract of the rabbit, one of its
natural hosts (36).
Nevertheless, since the experiment shown in Fig. 7A was
performed with bipA mutants constructed in the wild-type
strain background, it cannot be ruled out that the bacteria
never underwent a transition to the Bvgi phase in vivo in their
experimental host. To determine whether actual expression of
BipA in vivo provides B. pertussis with an adaptive advantage
when this pathogen is genetically forced to express its Bvgi
phase inside its host, we compared the ability of GMT1i to
colonize the murine respiratory tract with that of its isogenic
mutant carrying an in-frame deletion in bipA (GMT1i-DBA).
At the same time, this experiment potentially allowed us to
investigate whether BipA facilitates the initial interaction be-
tween B. pertussis and the respiratory epithelium by comparing
the level of colonization reached by the unmodulated GMT1i
and GMT1i-DBA cells (i.e., expressing and lacking BipA, re-
spectively) shortly after the inoculation.
As shown in Fig. 7B, although GMT1i-DBA showed a ten-
dency to colonize the murine respiratory tract at levels slightly
lower than GMT1i, this difference was not found to be signif-
icant at the beginning of the experiment. Interestingly, this
FIG. 6. Colonization of the mouse respiratory tract by two coin-
oculated B. pertussis strains, GMT1 and GMT1i. Groups of mice were
intranasally administered 50 l of PBS containing a mixed inoculum of
GMT1 and GMT1i (106 CFU and 106 CFU, respectively). At days 0
(four mice at least) and 8 (five mice at least), the animals were sacri-
ficed, and colonization at various sites in the respiratory tract was
determined and represented as a scatter diagram. Solid circles, GMT1;
shaded triangles, GMT1i. The dashed line indicates the lower limit of
detection. Asterisks denote a statistically significant difference (, P 
0.05; , P  0.01) between the two specified groups. Note that the
sensitivity of the statistical tests used to analyze data from the upper
and lower respiratory tract varies (see Materials and Methods).
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deficiency became more pronounced after 8 days of infection,
and thus the level of colonization reached by the bipA mutant
in the nasal septum at the end of the experiment was markedly
lower (P 0.002; i.e., P 0.01) than that of its parental strain.
It is important to point out that the actual inocula used in these
assays (as in all the animal experiments presented in this work)
were plated on BG-blood agar for viable counts to ensure that
equal numbers of CFU of the corresponding strain had been
delivered to the animals (n  8 in this particular experiment).
Search for serological markers indicating that B. pertussis
may modulate to the Bvgi phase in vivo. To indirectly assess
whether wild-type B. pertussis undergoes a transition to the
Bvgi phase in vivo, we screened sera from 100 patients (80
children and 20 adults) convalescent from pertussis for anti-
Bvgi-phase-specific antibodies. For that purpose, whole-cell
extracts of B. pertussis GMT1 and GMT1i were separated by
SDS-PAGE in adjacent gel lanes, transferred to polyvinylidene
difluoride, and probed with the corresponding serum sample.
As a positive control, duplicate lysates were probed with anti-
serum S3. Whereas the presence of an antibody response of
varying intensity against Bvg-phase-specific polypeptides and
Bvg-independent polypeptides (stars and arrows, respectively,
in Fig. 8) was often detectable in the sera, antibodies against
Bvgi-phase-specific polypeptides were not detected in any sam-
FIG. 7. Colonization of the mouse respiratory tract by bipA deletion mutants derived either from wild-type B. pertussis GMT1 (A) or from
GMT1i (B). Groups of mice were inoculated intranasally with 50 l of PBS containing 106 CFU of one of the experimental strains (A, GMT1 and
GMT1-DBA; B, GMT1i and GMT1i-DBA). At days 0 (three mice at least) and 8 (five mice at least), the animals were sacrificed, and colonization
at various sites of the respiratory tract was determined. Error bars represent 1 standard deviation. The dashed line indicates the lower limit of
detection. The asterisks denote a statistically significant difference (, P  0.01) between the two specified groups.
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ple. In light of these results, it was not surprising to likewise be
unable to detect this type of antibodies in sera from a nonnat-
ural host of B. pertussis (the mouse) infected with GMT1 for at
least 20 days (data not shown). In contrast, positive detection
of BipA by antiserum S3 in all the assays demonstrated that the
protein was present in the GMT1i extract. These results sug-
gest that if B. pertussis undergoes a transition to the Bvgi phase
in vivo, this phenomenon (temporally and/or spatially) passes
unnoticed by the immune system of its host.
DISCUSSION
Despite intense investigation since Lacey’s pioneering ob-
servations in 1960, the role of phenotypic modulation in the B.
pertussis life cycle remains an enigma. Results from two inde-
pendent reports performed with different experimental models
of respiratory infection showed that a Bvg-phase-locked mu-
tant of B. pertussis colonized the respiratory tract as efficiently
as the wild type (23, 27) whereas a Bvg-phase-locked mutant
was cleared soon after the beginning of the experiment, even
from the upper respiratory tract (23). In addition, both studies
showed that B. pertussis mutants manipulated to ectopically
express vrgs displayed a significant colonization defect in the
lower respiratory tract of mice. These observations suggest that
the Bvg phase of B. pertussis is necessary and sufficient for the
colonization of the murine respiratory tract. In contrast, the
observation that vrg6 was not required for full B. pertussis
virulence in the mouse, as was initially reported, and that the
transcriptional activity from the vrg6 promoter was very low
throughout the respiratory infection (23) argue against a role
for the Bvg phase during respiratory infection.
Paradoxically, the host seems to be the only niche where the
BvgAS-mediated transition to the Bvg phase in B. pertussis
can be expected to occur, since this Bordetella species, unlike
its close relative B. bronchiseptica (9), is not able to survive
under the nutrient-limiting conditions prevailing in the envi-
ronment. Alternatively, as other authors have proposed, the
Bvg phase could be a nonfunctional remnant that B. pertussis
retained from its progenitor, B. bronchiseptica (9). However,
even if the latter hypothesis is correct, the BvgAS-mediated
phenotypic modulation may still be necessary in the life cycle
of B. pertussis to facilitate its alteration at least between the
Bvg and the Bvgi phases, as the present study indicates.
First, our results show that B. pertussis expresses the Bvgi
phase in vitro when growing at 30°C, thereby confirming early
observations reported by Lacey, though in a different strain
background (21). Although a number of environmental signals
that Bordetella can sense may be important in vivo, tempera-
ture appears, in all likelihood, as a relevant modulator for B.
pertussis inside its host. In fact, the temperature in the human
nasal cavity ranges from 30.3 to 32.3°C when measured at an
ambient temperature of 23°C (6, 18) and is notably similar to
that of rabbits and small rodents (6, 17, 18). Therefore, it
seems likely that B. pertussis may express its Bvgi phase in that
niche. Consistent with this hypothesis, the only site of the
respiratory tract where GMT1i was able to persist at wild-type
levels was the upper respiratory tract. These results demon-
strate that the Bvg phase of B. pertussis is not strictly neces-
sary for the colonization of the upper respiratory tract of mice.
In conflict with a potential role for the Bvgi phase in vivo, we
failed to detect anti-BipA-specific antibodies in a large collec-
tion of sera from patients convalescent from pertussis. To
reconcile these observations, we propose that the Bvgi phase of
B. pertussis may be necessary for transmission between hosts, as
may be the case for B. bronchiseptica (8). According to this
hypothesis, which has been previously postulated for the mem-
bers of the B. bronchiseptica cluster (9), transition to the Bvgi
phase in response to low temperature in the distal upper re-
spiratory tract might facilitate the release of B. pertussis from
the nasal epithelium and/or the initial interaction with the new
host. In line with our results, this hypothetical transition should
be short-lasting enough to pass unnoticed to the immune sys-
tem of the host, thereby precluding the elicitation of an anti-
BipA-specific antibody response. Likewise, in its new host B.
pertussis may need to undergo a transition back to the Bvg
phase to prevent immune recognition of BipA and subsequent
production of anti-BipA antibodies.
Alternatively, although we have demonstrated by immuniz-
ing rats with GMT1i that B. pertussis BipA is highly immuno-
genic, the possibility remains that this protein may not be
immunogenic in humans naturally infected with B. pertussis. If
so, this feature of B. pertussis BipA would be exclusive of the
human pathogen since B. bronchiseptica BipA has also been
shown to be highly immunogenic in both naturally (Martı´nez
de Tejada and Lorenzo-Pajuelo, unpublished results) and ex-
perimentally infected animals (36).
Based on our results, several lines of evidence support a
hypothetical role of the Bvgi phase in the transmission of B.
pertussis. First, we have shown that a B. pertussis strain express-
ing the Bvgi phase (GMT1i grown under nonmodulating con-
ditions) can establish an initial colonization in the nasal sep-
FIG. 8. Assessment of the presence of anti-Bvgi-phase-specific an-
tibodies in sera from patients recovering from whooping cough.
Whole-cell extracts of GMT1, GMT1i, and GG2 were separated by
SDS-PAGE in adjacent gel lanes, transferred to polyvinylidene diflu-
oride, and probed with the corresponding serum. Results are repre-
sentative of the two main profiles obtained with the 100 sera tested.
Arrows and small stars show Bvg-independent and Bvg-phase-spe-
cific polypeptides, respectively. The positions of molecular size mark-
ers are indicated on the right (in kilodaltons).
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tum and the trachea of mice at wild-type levels even when
coinoculated with an isogenic strain expressing the Bvg phase
(GMT1 grown under nonmodulating conditions). More impor-
tantly, we demonstrated that in the absence of wild-type cells
GMT1i can persist in the upper respiratory tract as efficiently
as the wild-type strain. Taken together, these observations
suggest that a wild-type B. pertussis strain expressing the Bvgi
phase would be sufficiently well endowed to initiate the colo-
nization of the respiratory tract immediately after a transmis-
sion event.
Interestingly, our results show that the expression of BipA
conferred on GMT1i a noticeably higher (although non-statis-
tically significant) ability to establish colonization in both the
upper and lower respiratory tracts of mice compared with a
BipA isogenic strain. In this context, it is tempting to specu-
late that the poor interaction of the bipA derivative of GMT1i
with the murine respiratory tract at the initial stages of infec-
tion may have resulted at a later experimental time point in the
marked defect in colonization displayed by this strain in the
upper respiratory tract. On the other hand, results from the
coinoculation experiments show that the Bvg phase is also
better endowed than the Bvgi phase for the colonization of the
upper murine respiratory tract. This fact indicates that the Bvgi
phase does not appear to be a phenotypic phase specialized in
the colonization of any site of the respiratory tract, not even of
the nasal cavity. On the contrary, our observations are consis-
tent with the rapid transition from the Bvgi phase to the Bvg
phase postulated by our hypothesis. Finally, the fact that loss of
bipA by deletion in the wild-type strain background did not
cause any detectable colonization defect supports our hypoth-
esis that BipA expression is not strictly required for the colo-
nization of the respiratory tract but rather necessary only im-
mediately before and/or after a transmission event.
Nevertheless, a definitive conclusion cannot be formulated
since the specific conditions encountered by B. pertussis in the
mouse respiratory tract may not be adequate to promote a
transition to the Bvgi phase. Obviously, in this hypothetical
scenario, our animal model would not allow us to detect a
colonization defect caused by the absence of BipA. To address
this specific point, we plan to monitor bipA transcription dur-
ing the experimental respiratory infection with an in vivo re-
porter system. Furthermore, to more stringently test our hy-
pothesis, we plan to carry out experiments with B.
bronchiseptica (which possesses Bvgi phenotypes very similar to
those of the human pathogen [11 and results shown in the
present work]) and a model mimicking natural transmission to
investigate whether immunization with BipA confers on the
animals a certain degree of protection from being naturally
infected. Likewise, we will test whether BipA-immunized ani-
mals are less infectious than those not immunized but similarly
infected with wild-type B. bronchiseptica.
The biochemical characterization of GMT1 and GMT1i re-
vealed that, as shown in B. bronchiseptica (12, 36), BvgAS also
controls the expression of BipA at the level of transcription in
B. pertussis. This conclusion is in good agreement with recent
results published by Fuschlocher and collaborators with the
same mutant whose construction is reported in the present
work (14). In addition, our results show that BipA expression
is undetectable under fully modulating (Bvg phase) condi-
tions (16 mM nicotinic acid in our experiments). Consistent
with this, the bipA-lacZ fusion was found to be fully inactive
when introduced in the chromosome of a Bvg-phase-locked
mutant (GG2) and this strain did not produce detectable
amounts of BipA. Therefore, taken together, our results dem-
onstrate that bipA is a Bvgi-phase-specific gene. This conclu-
sion confirms previous studies on B. bronchiseptica bipA (12,
36) and B. pertussis bipA (14) but contradicts conclusions from
other authors reporting either upregulation of bipA under
Bvg-phase conditions, thus regarding bipA as a vrg (2) or
irregular transcriptional behaviors (16).
At the protein level, comparison of the Bvgi-phase-specific
antigenic profile of GMT1i with that of its isogenic bipA mu-
tant (GMT1i-DBA) indicates that BipA is the only B. pertussis
Bip detectable with serum raised against the Bvgi phase of
either B. bronchiseptica or B. pertussis. Interestingly, DNA mi-
croarray analyses have revealed the existence of additional
Bvgi-phase-specific genes in Bordetella (5). To circumvent a
potential interference caused by BipA (i.e., immunodomi-
nance) and to simultaneously complement at the protein level
this search for Bvgi-phase polypeptide-encoding genes, we plan
to use an antiserum raised against GMT1i-DBA to identify
Bvgi-phase polypeptides other than BipA.
Finally, our results also show that the Bvgi phases of B.
pertussis and B. bronchiseptica differ markedly in the range of
modulating conditions at which they are expressed. Thus,
whereas the Bvgi phase of B. bronchiseptica is detectable over
a narrow range of concentrations of nicotinic acid (approxi-
mately 0 to 1.6 mM) (11), B. pertussis needs a larger amount of
modulating agent (up to 2 mM nicotinic acid) to switch to the
Bvgi phase. In this regard, it is worth noting that, unlike strain
Tohama I, GMT1 belongs to a group of B. pertussis strains
characterized by their high sensitivity to modulation (24). In-
terestingly, with a B. bronchiseptica chimeric strain carrying the
bvgAS locus of B. pertussis Tohama I, it has been shown that
both upregulation and downregulation of bipA transcription
require levels of nicotinic acid twice as high as those shown
here for GMT1 (12). Whether these differences between the
Bvgi phases of B. pertussis and B. bronchiseptica are related to
peculiarities in their life cycle and their pathogenicity remains
to be elucidated.
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